NASDAQ: $CGEN
Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline.
The first engagement will be at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. This virtual event is scheduled for Thursday, February 26, 2026. Compugen management will host a fireside chat at 2:00 PM Eastern Time, followed by dedicated one-on-one meetings with interested parties.
Following the virtual conference, Compugen will present in person at the Leerink Partners 2026 Global Healthcare Conference. This highly anticipated event will take place on Monday, March 9, 2026, in Miami, Florida, U.S. The company’s participation includes a fireside chat session scheduled for 8:40 AM Eastern Time, alongside opportunities for private meetings.
Investors interested in tuning into the presentations can access live webcasts of both fireside chats directly through the Investor Relations section of Compugen’s official website at www.cgen.com. Furthermore, recordings of these sessions will be made available for replay shortly after the live broadcasts conclude.
About Compugen’s Pipeline Focus
Compugen continues to leverage its proprietary computational discovery platform, Unigen™, to identify novel biological targets for immuno-oncology treatments. The company’s current portfolio highlights its commitment to developing best-in-class and first-in-class therapeutic candidates:
- TIGIT Programs: Compugen maintains two distinct programs targeting TIGIT, utilizing its unique Fc-reduced technology. COM902, an Fc-reduced high-affinity anti-TIGIT antibody, is currently in Phase 1 development. Additionally, rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody whose TIGIT component originates from COM902, is in Phase 3 development via a license agreement with AstraZeneca.
- Other Key Assets: The company is also advancing COM701, a potential first-in-class Fc-reduced anti-PVRIG antibody, through Phase 1 studies. Furthermore, GS-0321 (formerly COM503), a high-affinity anti-IL-18 binding protein antibody, is licensed to Gilead.
- Early-Stage Research: Beyond these clinical programs, Compugen maintains a robust pipeline of early-stage immuno-oncology projects aimed at exploring new mechanisms for activating the body’s immune response against cancer.
These upcoming investor engagements provide a valuable forum to discuss the clinical trajectory of these assets and the strategic advantages afforded by Compugen’s AI/ML drug discovery foundation.